参考文献/References:
1 Vose JM, Wahl RL, Saleh M, et al. Muhicenter phase Ⅱ study of iodine-131 tositumomab for chemotherapy-relapsed/refractory lowgrade and transformed low-grade B-cell non-Hodgkin’s lymphomas[J]. J Clin Oncol, 2000, 18(6):1316-1323.
2 Kaminski MS, Zelenetz AD, Press OW, et al. Pivotal study of iodine-131 tositumomah for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin’s lymphomas[J]. J Clin Onool, 2001, 19(19):3918-3928.
3 Kaminski MS, Zelenetz AD, Leonard J, et al. Bexxar radioimmunotherapy produces a substantial number of durable complete responses in patients with multiply relapsed or refractory low grade or transformed low grade non-Hodgkin’s lymphoma[J]. Blood, 2002,100(11):356a.
4 Gregory SA, Zelenetz A, Knox S, et al. BexxarTM is an effective and well tolerated therapy in elderly patients with non-Hodgkin lymphoma (NHL)[J]. Proc Am Soc Clin Oncol, 2001, 20(7):285a.
5 Rohatiner A, Kaminski M, Leonard J, et al. BexxarTM radioimmunotherapy is efficacious in non Hodgkin’s lymphoma (NHL)patients with poor prognostic features[J]. Proc Am Soc Clin Oncol,2001, 20(7):286a.
6 Kaminski MS, Tuck M, Regan D, et al. High response rates and durable remissions in patients with previously untreated, advancedstage, follicular lymphoma treated with tositumomab and iodine- 131tositumomab (Bexxar(R))[J]. Blood,2002,100(11):356.
7 Leonard JP, Coleman M, Kostakoglu L, et al. Triple modality therapy for follicular low-grade lymphoma:initial treatment with fludarabine followed by BexxarTM (tositumomab and iodine-131 tositumomab)[J].Blood, 2001, 98(11):844a
8 Kaminski MS, Estes J, Zasadny KR, et al. Radioimmunotherapy with iodine- 131 tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma:updated results and long-term follow-up of the universityof Michigan experience[J]. Blood, 2000, 96(4):1259-1266.
9 Leonard JP, Frenette G, Dillman RO, et al. Interim safety and efficacy results of BexxarTM in a large multicenter expanded access study[J].Blood, 2001, 98(11):133a.
10 Kaminski MS. Tolerance of treatment subsequent to frontline BexxarTM (tositumomab and Ⅰ-131 tositumomab) in patients (pts) with follicular lymphoma[J]. Blood, 2001, 98(11):603a.
11 Schenkein DP, Leonard J, Harwood S, et al. Interim safety results of BexxarTM in a large multicenter expanded access study[J]. Proc Am Soc Clin Oncol, 2001, 20(7):285a.
12 Gregory SA, Coleman M, Dillman RO, et al. BexxarTMis a well-tolerated therapy in elderly patients with low-grade or transformed low-grade non-Hodgkin’s lymphoma (NHL)[J]. Blood, 2001, 98(11):605a.
13 Kaminski MS, Gregory SA, Fehrenbacher L, et al. Acute and delayed hematologic toxicities associated with BexxarTM therapy are modest:overall experience in patients with low-grade and transformed low-grade NHL[J]. Blood, 2001, 98(11):339a.
14 Gregory SA, Leonard J, Coleman M, et al. Relationship of degree of bone marrow involvement with hematologic toxicity in patients with non-Hodgkin’s lymphoma treated with tositumomab and iodine- 131tositumomab therapy[C]. Chicago:the 39th American Society of Clinical Oncology Annual Meeting, 2003.
15 Kaminski MS, Bennett J, Tuck M,et al. Lack of treatment-related MDS/AML in patients with follicular lymphoma after frontline therapy with tositumomab and iodine-131 tositumomab[C]. Chicago:the 39th American Society of Clinical Oncology Annual Meeting, 2003.
16 Hohenstein MA, Augustine SC, Rutar F, et al. Establishing an institutional model for the administration of tositumomab and Ⅰ-131tositumomab[J]. Semin Oncol, 2003, 30(suppl 4):39-49.